UK's Allergy Therapeutics expected H1 revenue up 7% yr/yr

Allergy Therapeutics

19/01/2026 07:20

Overview

UK biotech firm's H1 revenue expected to grow 7% yr/yr to £36.3 mln

Company launched Grassmuno in Germany

Cash position decreased after repaying shareholder loans

Outlook

Company expects full-year revenue to exceed previous year's results

Allergy Therapeutics sees sales momentum accelerating in H2 with Grassmuno commercialization

Company has access to £70 mln uncommitted fundin

Result Drivers

SUPPLY CHAIN IMPROVEMENTS - Improved operational execution and supply chain reliability contributed to growth

GERMAN MARKET RECOVERY - Recovery of existing product portfolio in Germany despite phase-out of TAV products

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
GBP 36.30 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Allergy Therapeutics PLC is GBP13.00, about 7.4% above its January 16 closing price of GBP12.10

Press Release: ID:nRSS3295Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)